Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Sanchez-Paulete, A.R. (Alfonso R.) | - |
dc.creator | Cueto, F.J. (Francisco J.) | - |
dc.creator | Martinez-Lopez, M. (María) | - |
dc.creator | Labiano, S. (Sara) | - |
dc.creator | Morales-Kastresana, A. (Aizea) | - |
dc.creator | Rodriguez-Ruiz, M.E. (María Esperanza) | - |
dc.creator | Jure-Kunkel, M. (María) | - |
dc.creator | Azpilicueta, A. (Arantza) | - |
dc.creator | Aznar, M.A. (María Ángela) | - |
dc.creator | Quetglas, J.I. (José Ignacio) | - |
dc.creator | Sancho, D. (David) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2016-03-04T16:08:51Z | - |
dc.date.available | 2016-03-04T16:08:51Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016 Jan;6(1):71-79 | es_ES |
dc.identifier.issn | 2159-8274 | - |
dc.identifier.uri | https://hdl.handle.net/10171/40135 | - |
dc.description.abstract | Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be rescued by immunomodulatory mAbs targeting PD-1 or CD137. Using Batf3−/− mice, which are defective for cross-presentation of cell-associated antigens, we show that BATF3-dependent dendritic cells (DC) are essential for the response to therapy with anti-CD137 or anti–PD-1 mAbs. Batf3−/− mice failed to prime an endogenous CTL-mediated immune response toward tumor-associated antigens, including neoantigens. As a result, the immunomodulatory mAbs could not amplify any therapeutically functional immune response in these mice. Moreover, administration of systemic sFLT3L and local poly-ICLC enhanced DC-mediated cross-priming and synergized with anti–CD137- and anti–PD-1–mediated immunostimulation in tumor therapy against B16-ovalbumin–derived melanomas, whereas this function was lost in Batf3−/− mice. These experiments show that cross-priming of tumor antigens by FLT3L- and BATF3-dependent DCs is crucial to the efficacy of immunostimulatory mAbs and represents a very attractive point of intervention to enhance their clinical antitumor effects. | es_ES |
dc.description.sponsorship | MICINN (SAF2008-03294 and SAF2011-22831), Departamento de salud del Gobierno de Navarra, Redes temáticas de investigación cooperativa RETIC (RD06/0020/0065), and the European commission 7th framework program (ENCITE and IACT). Spanish Ministry of Economy and Competitiveness (SAF-2013-42920R) and the European Research Council (ERC Starting Independent Researcher Grant 2010, ERC-2010-StG 260414). European Commission (635122-PROCROP H2020) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Association for Cancer Research | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/635122 | - |
dc.rights | info:eu-repo/semantics/openAccess | * |
dc.subject | Cancer immunotherapy | es_ES |
dc.subject | Immunomodulatory | es_ES |
dc.subject | Anti-PD-1 and anti-CD137 | es_ES |
dc.subject | Dentritic cells | es_ES |
dc.title | Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://cancerdiscovery.aacrjournals.org/content/6/1/71.long | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.